FY2024 EPS Estimates for Cosmos Health Inc. (NASDAQ:COSM) Reduced by Taglich Brothers

Cosmos Health Inc. (NASDAQ:COSM) – Investment analysts at Taglich Brothers decreased their FY2024 earnings estimates for Cosmos Health in a report issued on Monday, September 16th. Taglich Brothers analyst H. Halpern now expects that the company will earn ($0.48) per share for the year, down from their prior estimate of ($0.47). The consensus estimate for Cosmos Health’s current full-year earnings is ($0.47) per share. Taglich Brothers also issued estimates for Cosmos Health’s Q4 2024 earnings at ($0.11) EPS.

Cosmos Health (NASDAQ:COSM) last announced its quarterly earnings results on Tuesday, August 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.05. Cosmos Health had a negative return on equity of 5.83% and a negative net margin of 38.19%. The firm had revenue of $13.21 million during the quarter, compared to the consensus estimate of $15.25 million.

Cosmos Health Trading Down 2.6 %

Shares of Cosmos Health stock opened at $1.11 on Thursday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.17 and a current ratio of 1.35. The company has a fifty day simple moving average of $1.16 and a 200-day simple moving average of $0.87. Cosmos Health has a 12-month low of $0.47 and a 12-month high of $2.05.

Hedge Funds Weigh In On Cosmos Health

An institutional investor recently bought a new position in Cosmos Health stock. Armistice Capital LLC bought a new stake in Cosmos Health Inc. (NASDAQ:COSM) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,334,937 shares of the company’s stock, valued at approximately $1,882,000. Armistice Capital LLC owned about 7.89% of Cosmos Health as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 12.61% of the company’s stock.

About Cosmos Health

Cosmos Health Inc provides proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter medications, cosmetics, nursery, health care and baby products, and medical devices. Its nutraceutical product portfolio includes Sky Premium Life and Mediterranation. The company serves wholesale pharmaceutical distributors and independent retail pharmacies.